Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89.6M
-
Number of holders
-
72
-
Total 13F shares, excl. options
-
38.7M
-
Shares change
-
+1.04M
-
Total reported value, excl. options
-
$1.81B
-
Value change
-
+$21.7M
-
Number of buys
-
49
-
Number of sells
-
-43
-
Price
-
$47.00
Significant Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q3 2021
102 filings reported holding VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2021.
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 72 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.7M shares
of 89.6M outstanding shares and own 43.21% of the company stock.
Largest 10 shareholders include Alphabet Inc. (11M shares), WELLINGTON MANAGEMENT GROUP LLP (4.59M shares), FMR LLC (3.48M shares), Casdin Capital, LLC (3.04M shares), Redmile Group, LLC (1.87M shares), BAKER BROS. ADVISORS LP (1.42M shares), VANGUARD GROUP INC (1.28M shares), ARK Investment Management LLC (1.27M shares), JANUS HENDERSON GROUP PLC (1.16M shares), and Rock Springs Capital Management LP (963K shares).
This table shows the top 72 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.